Results 221 to 230 of about 28,823 (297)

Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India. [PDF]

Cureus
Kalra S, Bhattacharya S, Dhingra A, Das S, Kapoor N, Shaikh S, Kolapkar V, Lokesh Kumar RV, Patel K, Kotwal R.   +9 more
europepmc   +1 more source

Dipeptidyl peptidase‐4 inhibitor approaches

Journal of Diabetes, 2016
openaire   +1 more source

Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7592-7596, August 2026.
Huilin Tang, Bingyu Zhang, Yiwen Lu, Ying Lu, Anastassia Amaro, Yuan Lu, David A. Wolk, Yong Chen   +7 more
wiley   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial". [PDF]

Diabetes Obes Metab
europepmc   +1 more source

Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor. [PDF]

Adv Ther
Evans M, Husain M, Srivastava A, Mangla KK, Kuhlman AB, Lingvay I.   +5 more
europepmc   +1 more source

Risk of Psychiatric Worsening With GLP‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7048-7057, August 2026.
ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia. [PDF]

PLoS One
Harris DD, Sabe SA, Broadwin M, Stone C, Bellam K, Malhotra A, Abid MR, Sellke FW.   +7 more
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7367-7379, August 2026.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy [PDF]

, 2012
Baptist Gallwitz
core